KLRK1 and central nervous system cancer: Glioma cells express ligands for activating immune receptors like natural killer group 2 member D (NKG2D) or DNAX accessory molecule (DNAM)-1 [8–11], and should therefore be prone to recognition and elimination by the immune system.